An Open-label Study in Healthy Male Participants to Determine the Mass Balance, Absolute Bioavailability and Pharmacokinetics of Daprodustat, Administered as a Single Intravenous Microtracer (Concomitant With an Oral Dose of Non-radiolabelled Daprodustat) and a Single, Oral Radiolabelled Dose
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Daprodustat (Primary) ; Daprodustat (Primary)
- Indications Anaemia; Diabetic foot ulcer; Perioperative ischaemia; Tendon injuries
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 23 Aug 2017 Planned End Date changed from 3 Oct 2017 to 20 Nov 2017.
- 23 Aug 2017 Planned primary completion date changed from 3 Oct 2017 to 20 Nov 2017.
- 23 Aug 2017 Planned initiation date changed from 4 Sep 2017 to 2 Oct 2017.